Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We develop, manufacture and market an integrated platform for high resolution genetic analysis. We have developed a technology to study the synthesis, composition, structure, and regulation of DNA. Combining advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, we created a technology platform using our proprietary single molecule, real-time, or SMRT, technology. Our SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events as they occur. The ability to observe single molecule events in real time provides the scientific community with an advanced tool for investigating basic biochemical processes such as DNA synthesis. Our SMRT technology has the potential to advance scientific understanding by providing a window into biological processes that has not previously been open. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-1.69 |
| Quarterly EPS Est: | -0.36 |
| PEG Ratio: | -.06 |
|
Mean Recommendation: View Summary / View All |
4.33 |
Data is provided by Zacks Investment Research

